{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:08:05Z","timestamp":1788952085742,"version":"build-2803163510"},"reference-count":92,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>More than half of cases of heart failure (HF) now occur with preserved ejection fraction (HFpEF), a heterogeneous syndrome strongly influenced by comorbidities such as obesity, hypertension, diabetes and atrial fibrillation. Despite recent evidence supporting SGLT2 inhibitors and mineralocorticoid receptor antagonists, morbidity and mortality remain substantial. GLP1 receptor agonists, initially developed for type 2 diabetes, induce profound weight loss and have demonstrated benefits across cardiovascular, renal and metabolic pathways relevant to HFpEF. Recent randomized controlled trials (RCTs) in obesity\u2011related HFpEF showed clinically meaningful improvements in symptoms, functional capacity and inflammatory biomarkers with semaglutide in STEP\u2011HFpEF, and a reduction in the composite of cardiovascular death or worsening HF events with tirzepatide in SUMMIT. Mechanistic evidence suggests effects on natriuresis, inflammation, cardiac remodelling, endothelial function and epicardial adipose tissue quality and volume. This review summarizes the pathophysiological rationale, clinical evidence, mechanistic insights and therapeutic positioning of GLP1 receptor agonists in HFpEF.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-glp1-receptor-agonists-in-heart-failure-with-preserved-ejection-fraction-hfpef-beyond-weight-loss-a-condensed-scientific-review\n\nThis article is part of the Real-world evidence on the use of GLP1 receptor agonists Special Issue: https:\/\/www.drugsincontext.com\/special_issues\/real-world-evidence-on-the-use-of-glp1-receptor-agonists<\/jats:p>","DOI":"10.7573\/dic.2025-12-4","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:13:31Z","timestamp":1780910011000},"page":"1","source":"Crossref","is-referenced-by-count":1,"title":["GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) \u2013 beyond weight loss: a condensed scientific review"],"prefix":"10.7573","volume":"15","author":[{"given":"Elyzabeth","family":"Roy","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03vs03g62","id-type":"ROR","asserted-by":"publisher"}],"name":"Montreal Heart Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Parent","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03vs03g62","id-type":"ROR","asserted-by":"publisher"}],"name":"Montreal Heart Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anique","family":"Ducharme","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03vs03g62","id-type":"ROR","asserted-by":"publisher"}],"name":"Montreal Heart Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tChen QF, Chen L, Katsouras CS, et al. Global burden of heart failure and its underlying causes in 204 countries and territories, 1990\u20132021. Eur Heart J Qual Care Clin Outcomes. 2025;11(4):493\u2013509. https:\/\/doi.org\/10.1093\/ehjqcco\/qcae110","DOI":"10.1093\/ehjqcco\/qcae110"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tMcDonald M, Virani S, Chan M, et al. CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol. 2021;37(4):531\u2013546. https:\/\/doi. org\/10.1016\/j.cjca.2021.01.017","DOI":"10.1016\/j.cjca.2021.01.017"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tKapelios CJ, Shahim B, Lund LH, Savarese G. Epidemiology, clinical characteristics and cause-specific outcomes in heart failure with preserved ejection fraction. Card Fail Rev. 2023;9:e14. https:\/\/doi.org\/10.15420\/cfr.2023.03","DOI":"10.15420\/cfr.2023.03"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tDhore-Patil A, Thannoun T, Samson R, Le Jemtel TH. Diabetes mellitus and heart failure with preserved ejection fraction: role of obesity. Front Physiol. 2022;12:785879. https:\/\/doi.org\/10.3389\/fphys.2021.785879","DOI":"10.3389\/fphys.2021.785879"},{"key":"ref4","unstructured":"5.\tWorld Health Organization. Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed August 12, 2025."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tNCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027\u20131050. https:\/\/doi.org\/10.1016\/s0140-6736(23)02750-2","DOI":"10.1016\/S0140-6736(23)02750-2"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tKittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(18):1835\u20131878. https:\/\/doi.org\/10.1016\/j.jacc.2023.03.393","DOI":"10.1016\/j.jacc.2023.03.393"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tMcDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tHeidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757\u20131780. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011","DOI":"10.1016\/j.jacc.2021.12.011"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tAnker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/nejmoa2107038","DOI":"10.1056\/NEJMoa2107038"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tSolomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u20131098. https:\/\/doi.org\/10.1056\/nejmoa2206286","DOI":"10.1056\/NEJMoa2206286"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tPitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u20131392. https:\/\/doi.org\/10.1056\/nejmoa1313731","DOI":"10.1056\/NEJMoa1313731"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tPetrie M, Borlaug B, Buchholtz K, et al. HERMES: effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. J Card Fail. 2024;30(1):126. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.cardfail.2023.10.024","DOI":"10.1016\/j.cardfail.2023.10.024"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tKosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u20131084. https:\/\/doi.org\/10.1056\/NEJMoa2306963","DOI":"10.1056\/NEJMoa2306963"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tKosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa2313917","DOI":"10.1056\/NEJMoa2313917"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tDucharme A, Zieroth S, Ahooja V, et al. Canadian Cardiovascular Society-Canadian Heart Failure Society focused clinical practice update of patients with differing heart failure phenotypes. Can J Cardiol. 2023;39(8):1030\u20131040. https:\/\/doi.org\/10.1016\/j.cjca.2023.04.022","DOI":"10.1016\/j.cjca.2023.04.022"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tStoicescu L, Cri\u015fan D, Morgovan C, Avram L, Ghibu S. Heart failure with preserved ejection fraction: the pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach. Int J Mol Sci. 2024;25(2):794. https:\/\/doi.org\/10.3390\/ijms25020794","DOI":"10.3390\/ijms25020794"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tBorlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9): 507\u2013515. https:\/\/doi.org\/10.1038\/nrcardio.2014.83","DOI":"10.1038\/nrcardio.2014.83"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tvan Heerebeek L, Hamdani N, Falc\u00e3o-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126(7):830\u2013839. https:\/\/doi.org\/10.1161\/circulationaha.111.076075","DOI":"10.1161\/CIRCULATIONAHA.111.076075"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tPaulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263\u2013271. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092","DOI":"10.1016\/j.jacc.2013.02.092"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tTesta M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28(4):964\u2013971. https:\/\/doi.org\/10.1016\/S0735-1097(96)00268-9","DOI":"10.1016\/S0735-1097(96)00268-9"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tNymo SH, Hulthe J, Ueland T, et al. Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. Eur J Heart Fail. 2014;16(1):68\u201375. https:\/\/doi.org\/10.1093\/eurjhf\/hft125","DOI":"10.1093\/eurjhf\/hft125"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tMarkousis-Mavrogenis G, Tromp J, Ouwerkerk W, et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail. 2019;21(8):965\u2013973. https:\/\/doi.org\/10.1002\/ejhf.1482","DOI":"10.1002\/ejhf.1482"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tLi H, Chen C, Wang DW. Inflammatory cytokines, immune cells, and organ interactions in heart failure. Front Physiol. 2021;12:695047. https:\/\/doi.org\/10.3389\/fphys.2021.695047","DOI":"10.3389\/fphys.2021.695047"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tPaulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263\u2013271. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092","DOI":"10.1016\/j.jacc.2013.02.092"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tPich\u00e9 M-E, Poirier P. Obesity, ectopic fat and cardiac metabolism. Expert Rev Endocrinol Metab. 2018;13(4):213\u2013221. https:\/\/doi.org\/10.1080\/17446651.2018.1500894","DOI":"10.1080\/17446651.2018.1500894"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tIacobellis G. Epicardial and pericardial fat: close, but very different. Obesity. 2009;17(4):625\u2013625. https:\/\/doi. org\/10.1038\/oby.2008.575","DOI":"10.1038\/oby.2008.575"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tIacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol. 2015;11(6):363\u2013371. https:\/\/doi.org\/10.1038\/nrendo.2015.58","DOI":"10.1038\/nrendo.2015.58"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tPacker M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol. 2018;71(20):2360\u20132372. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.509","DOI":"10.1016\/j.jacc.2018.03.509"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tFukushima A, Lopaschuk GD. Cardiac fatty acid oxidation in heart failure associated with obesity and diabetes. Biochim Biophys Acta. 2016;1861(10):1525\u20131534. https:\/\/doi.org\/10.1016\/j.bbalip.2016.03.020","DOI":"10.1016\/j.bbalip.2016.03.020"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tTaegtmeyer H, Young ME, Lopaschuk GD, et al. Assessing cardiac metabolism: a scientific statement from the American Heart Association. Circ Res. 2016;118(10):1659\u20131701. https:\/\/doi.org\/10.1161\/res.0000000000000097","DOI":"10.1161\/RES.0000000000000097"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tAbel ED. Myocardial insulin resistance and cardiac complications of diabetes. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5(2):219\u2013226. https:\/\/doi.org\/10.2174\/1568008054064869","DOI":"10.2174\/1568008054064869"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tZlobine I, Gopal K, Ussher JR. Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochim Biophys Acta. 2016;1861(10):1555\u20131568. https:\/\/doi.org\/10.1016\/j.bbalip.2016.02.011","DOI":"10.1016\/j.bbalip.2016.02.011"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tWende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta. 2010;1801(3):311\u2013319. https:\/\/doi.org\/10.1016\/j. bbalip.2009.09.023","DOI":"10.1016\/j.bbalip.2009.09.023"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tUssher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocrine Rev. 2012;33(2):187\u2013215. https:\/\/doi. org\/10.1210\/er.2011-1052","DOI":"10.1210\/er.2011-1052"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tRachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7\u201336) amide in patients with NIDDM. Diabetes. 1996;45(11): 1524\u20131530. https:\/\/doi.org\/10.2337\/diab.45.11.1524","DOI":"10.2337\/diab.45.11.1524"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tDuncan RE, Ahmadian M, Jaworski K, Sarkadi-Nagy E, Sul HS. Regulation of lipolysis in adipocytes. Annu Rev Nutr. 2007;27(1):79\u2013101. https:\/\/doi.org\/10.1146\/annurev.nutr.27.061406.093734","DOI":"10.1146\/annurev.nutr.27.061406.093734"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tWang T-Y, Yang Q, Cheng X-Y, Ding J-C, Hu P-F. Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction. Heart Fail Rev. 2024;30(1):17\u201338. https:\/\/ doi.org\/10.1007\/s10741-024-10438-2","DOI":"10.1007\/s10741-024-10438-2"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tJensterle M, Rizzo M, Haluzik M, Janez A. Efficacy of GLP1 RA approved for weight management in patients with or without diabetes: a narrative review. Adv Ther. 2022;39(6):2452\u20132467. https:\/\/doi.org\/10.1007\/s12325-022-02153-x","DOI":"10.1007\/s12325-022-02153-x"},{"key":"ref39","unstructured":"40.\tDeanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773\u2013786. https:\/\/doi. org\/10.1016\/S0140-6736(24)01498-3"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.\tLincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u20132232. https:\/\/doi.org\/10.1056\/nejmoa2307563","DOI":"10.1056\/NEJMoa2307563"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.\tFudim M, White J, Pagidipati NJ, et al. Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes. Circulation. 2019;140(20):1613\u20131622. https:\/\/doi. org\/10.1161\/circulationaha.119.041659","DOI":"10.1161\/CIRCULATIONAHA.119.041659"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tHolman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u20131239. https:\/\/doi.org\/10.1056\/nejmoa1612917","DOI":"10.1056\/NEJMoa1612917"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tMcGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001\u20132012. https:\/\/doi.org\/10.1056\/nejmoa2501006","DOI":"10.1056\/NEJMoa2501006"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tBonaca MP, Catarig A-M, Houlind K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;405(10489):1580\u20131593. https:\/\/doi.org\/10.1016\/s0140-6736(25)00509-4","DOI":"10.1016\/S0140-6736(25)00509-4"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.\tPerkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u2013121. https:\/\/doi.org\/10.1056\/nejmoa2403347","DOI":"10.1056\/NEJMoa2403347"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tButler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635\u20131648. https:\/\/doi.org\/10.1016\/S0140-6736(24)00469-0","DOI":"10.1016\/S0140-6736(24)00469-0"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tMadamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176(3):611\u2013617. https:\/\/doi.org\/10.1016\/j.ijcard.2014.08.007","DOI":"10.1016\/j.ijcard.2014.08.007"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tNauck MA, D\u2018Alessio DA. Tirzepatide, a dual GIP\/GLP1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. https:\/\/doi.org\/10.1186\/s12933-022-01604-7","DOI":"10.1186\/s12933-022-01604-7"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.\tMelson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes. 2025;49(3):433\u2013451. https:\/\/doi.org\/10.1038\/s41366-024-01473-y","DOI":"10.1038\/s41366-024-01473-y"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.\tSamms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP1? Trends Endocrinol Metab. 2020;31(6):410\u2013421. https:\/\/doi.org\/10.1016\/j.tem.2020.02.006","DOI":"10.1016\/j.tem.2020.02.006"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.\tPacker M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u2013437. https:\/\/doi.org\/10.1056\/NEJMoa2410027","DOI":"10.1056\/NEJMoa2410027"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.\tJorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) \u2013 a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69\u201377. https:\/\/doi.org\/10.1002\/ejhf.657","DOI":"10.1002\/ejhf.657"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.\tMargulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction. JAMA. 2016;316(5):500. https:\/\/doi.org\/10.1001\/jama.2016.10260","DOI":"10.1001\/jama.2016.10260"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.\tNeves JS, Vasques-N\u00f3voa F, Borges-Canha M, et al. Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post hoc analysis of the FIGHT trial. Diabetes Obes Metab. 2023;25(1):189\u2013197. https:\/\/ doi.org\/10.1111\/dom.14862","DOI":"10.1111\/dom.14862"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.\tRedouane B, Greene SJ, Fudim M, et al. Effects of liraglutide on worsening renal function among patients with heart failure with reduced ejection fraction: insights from the FIGHT Trial. Circ Heart Fail. 2020;13(5):e006758. https:\/\/doi. org\/10.1161\/circheartfailure.119.006758","DOI":"10.1161\/CIRCHEARTFAILURE.119.006758"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57.\tPratley RE, Tuttle KR, Rossing P, et al. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW Trial. J Am Coll Cardiol. 2024;84(17):1615\u20131628. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.004","DOI":"10.1016\/j.jacc.2024.08.004"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58.\tFerreira JP, Sharma A, Butler J, et al. Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure. J Clin Endocrinol Metab. 2023;109(1):4\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgad398","DOI":"10.1210\/clinem\/dgad398"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59.\tBergman RN, Stefanovski D, Buchanan TA, et al. A better index of body adiposity. Obesity. 2011;19(5):1083\u20131089. https:\/\/doi.org\/10.1038\/oby.2011.38","DOI":"10.1038\/oby.2011.38"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60.\tLee CMY, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol. 2008;61(7):646\u2013653. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.08.012","DOI":"10.1016\/j.jclinepi.2007.08.012"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.\tTewari A, Kumar G, Maheshwari A, Tewari V, Tewari J. Comparative evaluation of waist-to-height ratio and BMI in predicting adverse cardiovascular outcome in people with diabetes: a systematic review. Cureus. 2023;15(5):e38801. https:\/\/doi.org\/10.7759\/cureus.38801","DOI":"10.7759\/cureus.38801"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.\tAlbulushi A, Tanoh DB, Almustafa A, Al Matrooshi N, Zolty R, Lowes B. Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis. Cardiovasc Diabetol. 2024;23(1):324. https:\/\/doi.org\/10.1186\/s12933-024-02415-8","DOI":"10.1186\/s12933-024-02415-8"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63.\tChait A, Den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020;7:22. https:\/\/doi.org\/10.3389\/fcvm.2020.00022","DOI":"10.3389\/fcvm.2020.00022"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64.\tVolpe M, Gallo G. Obesity and cardiovascular disease: an executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. https:\/\/doi.org\/10.3389\/fcvm.2023.1136340","DOI":"10.3389\/fcvm.2023.1136340"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65.\tManolis AA, Manolis TA, Manolis AS. Neurohumoral activation in heart failure. Int J Mol Sci. 2023; 24(20):15472. https:\/\/doi.org\/10.3390\/ijms242015472","DOI":"10.3390\/ijms242015472"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"66.\tFaulkner JL, Bruder-Nascimento T, Belin De Chantem\u00e8le EJ. The regulation of aldosterone secretion by leptin. Curr Opin Nephrol Hypertens. 2018;27(2):63\u201369. https:\/\/doi.org\/10.1097\/mnh.0000000000000384","DOI":"10.1097\/MNH.0000000000000384"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"67.\tJalil JE, Gabrielli L, Ocaranza MP, et al. New mechanisms to prevent heart failure with preserved ejection fraction using glucagon-like peptide-1 receptor agonism (GLP1 RA) in metabolic syndrome and in type 2 diabetes: a review. Int J Mol Sci. 2024;25(8):4407. https:\/\/doi.org\/10.3390\/ijms25084407","DOI":"10.3390\/ijms25084407"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"68.\tGonz\u00e1lez A, L\u00f3pez B, Ravassa S, et al. Myocardial interstitial fibrosis in hypertensive heart disease: from mechanisms to clinical management. Hypertension. 2024;81(2):218\u2013228. https:\/\/doi.org\/10.1161\/hypertensionaha.123.21708","DOI":"10.1161\/HYPERTENSIONAHA.123.21708"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"69.\tGuo X, Zhang J, Huang M, et al. Systemic inflammation is associated with myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy. ESC Heart Fail. 2025;12(1):582\u2013591. https:\/\/doi.org\/10.1002\/ehf2.15109","DOI":"10.1002\/ehf2.15109"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"70.\tPaulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ Res. 2021;128(10):1451\u20131467. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318159","DOI":"10.1161\/CIRCRESAHA.121.318159"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"71.\tJia G, Aroor AR, Hill MA, Sowers JR. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;72(3):537\u2013548. https:\/\/doi.org\/10.1161\/ hypertensionaha.118.11065","DOI":"10.1161\/HYPERTENSIONAHA.118.11065"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"72.\tZile MR, Baicu CF, Ikonomidis JS, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131(14):1247\u20131259. https:\/\/doi.org\/10.1161\/ circulationaha.114.013215","DOI":"10.1161\/CIRCULATIONAHA.114.013215"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"73.\tMa Y-L, Kong C-Y, Guo Z, et al. Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5\/NR4a1 axis. Nat Commun. 2024;15(1):4757. https:\/\/doi.org\/10.1038\/s41467- 024-48970-2","DOI":"10.1038\/s41467-024-48970-2"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"74.\tWithaar C, Meems LMG, Markousis-Mavrogenis G, et al. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovasc Res. 2021;117(9):2108\u20132124. https:\/\/doi.org\/10.1093\/cvr\/cvaa256","DOI":"10.1093\/cvr\/cvaa256"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"75.\tZhang L-H, Pang X-F, Bai F, et al. Preservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT1\/AT2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart. Cardiovasc Drugs Ther. 2015;29(3):243\u2013255. https:\/\/doi.org\/10.1007\/s10557-015-6592-7","DOI":"10.1007\/s10557-015-6592-7"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"76.\tMartins FF, Marinho TS, Cardoso LEM, et al. Semaglutide (GLP1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice. Cell Biochem Funct. 2022;40(8):903\u2013913. https:\/\/doi.org\/10.1002\/cbf.3751","DOI":"10.1002\/cbf.3751"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"77.\tDutour A, Abdesselam I, Ancel P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab. 2016;18(9):882\u2013891. https:\/\/doi.org\/10.1111\/dom.12680","DOI":"10.1111\/dom.12680"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"78.\tIacobellis G, Villasante Fricke AC. Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity. J Endocr Soc. 2020;4(4):bvz042. https:\/\/doi.org\/10.1210\/jendso\/bvz042","DOI":"10.1210\/jendso\/bvz042"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"79.\tManubolu VS, Lakshmanan S, Kinninger A, et al. Effect of semaglutide on epicardial adipose tissue in type 2 diabetes: insights from the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) randomized trial. J Am Coll Cardiol. 2024;84(9):865\u2013867. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.065","DOI":"10.1016\/j.jacc.2024.05.065"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"80.\tIncalza MA, D\u2019Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1\u201319. https:\/\/doi.org\/10.1016\/j.vph.2017.05.005","DOI":"10.1016\/j.vph.2017.05.005"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"81.\tColombo SL, Moncada S. AMPKalpha1 regulates the antioxidant status of vascular endothelial cells. Biochem J. 2009;421(2):163\u2013169. https:\/\/doi.org\/10.1042\/bj20090613","DOI":"10.1042\/BJ20090613"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"82.\tChen Z, Peng IC, Sun W, et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res. 2009;104(4):496\u2013505. https:\/\/doi.org\/10.1161\/circresaha.108.187567","DOI":"10.1161\/CIRCRESAHA.108.187567"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"83.\tGreen K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes. 2004;53(Suppl. 1):S110\u2013S118. https:\/\/doi.org\/10.2337\/diabetes.53.2007.S110","DOI":"10.2337\/diabetes.53.2007.S110"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"84.\tBrand MD. Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. Free Radic Biol Med. 2016;100:14\u201331. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2016.04.001","DOI":"10.1016\/j.freeradbiomed.2016.04.001"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"85.\tWu S, Zou M-H. AMPK, mitochondrial function, and cardiovascular disease. Int J Mol Sci. 2020;21(14):4987. https:\/\/doi. org\/10.3390\/ijms21144987","DOI":"10.3390\/ijms21144987"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"86.\tAlfadda AA, Sallam RM. Reactive oxygen species in health and disease. J Biomed Biotechnol. 2012;2012:936486. https:\/\/doi.org\/10.1155\/2012\/936486","DOI":"10.1155\/2012\/936486"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"87.\tDelfino RJ, Staimer N, Vaziri ND. Air pollution and circulating biomarkers of oxidative stress. Air Qual Atmos Health. 2011;4(1):37\u201352. https:\/\/doi.org\/10.1007\/s11869-010-0095-2","DOI":"10.1007\/s11869-010-0095-2"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"88.\tSchiattarella GG, Altamirano F, Tong D, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019;568(7752):351\u2013356. https:\/\/doi.org\/10.1038\/s41586-019-1100-z","DOI":"10.1038\/s41586-019-1100-z"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"89.\tDurak A, Turan B. Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts. J Physiol Biochem. 2023;79(2):297\u2013311. https:\/\/doi.org\/10.1007\/s13105-022-00939-9","DOI":"10.1007\/s13105-022-00939-9"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"90.\tLuna-Marco C, de Maranon AM, Hermo-Argibay A, et al. Effects of GLP1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox Biol. 2023;66:102849. https:\/\/doi.org\/10.1016\/j.redox.2023.102849","DOI":"10.1016\/j.redox.2023.102849"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"91.\tKalayci A, Januzzi JL, Mitsunami M, et al. Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2025;11(6):552\u2013561. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf037","DOI":"10.1093\/ehjcvp\/pvaf037"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"92.\tShokravi A, Seth J, Mancini GBJ. Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis. Cardiovasc Diabetol. 2025;24:370. https:\/\/doi.org\/10.1186\/s12933-025-02900-8","DOI":"10.1186\/s12933-025-02900-8"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/06\/dic.2025-12-4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:10:10Z","timestamp":1788948610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/glp1-receptor-agonists-in-heart-failure-with-preserved-ejection-fraction-hfpef-beyond-weight-loss-a-condensed-scientific-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":92,"URL":"https:\/\/doi.org\/10.7573\/dic.2025-12-4","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"dic.2025-12-4"}}